The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

166 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma (mNPC) patients is not unknown. Through the observational prospective clinical trial, sensitivity, specificity, positive and negative predictive values of CTC in diagnosis of mNPC patients will be gained. Further, the value of CTC in outcome prediction of mNPC patients will be uncovered.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer

NCT03724500

Non-small Cell Lung Cancer

UNKNOWN

A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases

NCT03257735

Lung Cancer Brain Metastases Cerebrospinal Fluid +1 more

UNKNOWN

Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy

NCT02155426

Non Small Cell Lung Cancer

UNKNOWN

Therapeutic Response Evaluation by CTC Expansion System

NCT04972461

Circulating Tumor Cells

UNKNOWN

Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma

NCT02211677

Nasopharyngeal Neoplasms Blood Cell Count Neoplasm Staging +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

the number of circulating tumor cells

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

the number of circulating tumor cells

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or radiologically confirmed nasopharyngeal non-keratinizing carcinoma (WHO II, III).
* NPC patients with distant metastasis including synchronous distant metastasis at diagnosis and metachronous distant metastasis after radical treatment.
* A Karnofsky performance status score more than 70.
* The participants provided written informed consent.

Exclusion Criteria

* A history of previous or synchronous malignant tumors.
* Suffering from severe mental illness synchronously.
* Suffering from severe heart or lung diseases.
* Obvious abnormality in liver and renal function.
* Women in pregnancy or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No